UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 22, 2010

CADENCE PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Registrant’s telephone number, including area code: (858) 436-1400

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Cadence Pharmaceuticals, Inc. (the “Company”) previously entered into an Amended and Restated Loan and Security Agreement with Oxford Finance Corporation, Silicon Valley Bank and GE Business Financial Services, Inc. (the “Lenders”) dated June 18, 2010, which provided the Company with a growth capital loan facility of up to $30 million. The first advance under the loan facility, in the amount of $20 million, was made in June 2010, and the second advance of $10 million was subject to approval by the U.S. Food and Drug Administration (“FDA”) of the Company’s investigational product candidate, OFIRMEV™ (acetaminophen) injection, on or before December 31, 2010. The loan agreement provided that the interest rate for each applicable drawdown would be equal the greater of (i) 11.25% and (ii) the sum of (a) the one-month U.S. London Interbank Offer Rate (LIBOR) reported in the Wall Street Journal three (3) Business Days prior to the drawdown date plus (b) 10.98%.

On November 22, 2010, the Company entered into an amendment to the loan agreement that provides for a reduced interest rate for the $10 million advance, but does not affect the interest rate for the $20 million initial advance, which is 11.33%. The interest rate for the $10 million advance is 10.08%, which is equal to the greater of (a) 10.08% and (b) the sum of the one-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date, plus 9.83%. The Company became eligible to drawdown the remaining $10 million on November 2, 2010, the day the Company received FDA approval for OFIRMEV, and the Lenders made the $10 million advance on November 23, 2010.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the amendment, a copy of which is attached as an exhibit hereto and incorporated herein by reference and the loan agreement, a copy of which is attached as an exhibit to our Form 8-K filed on June 21, 2010.

The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein and made a part hereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX